Leerink Partnrs Forecasts Reduced Earnings for Moderna

Moderna, Inc. (NASDAQ:MRNA - Free Report) - Stock analysts at Leerink Partnrs decreased their FY2025 earnings estimates for Moderna in a research report issued to clients and investors on Sunday, November 17th. Leerink Partnrs analyst M. Foroohar now anticipates that the company will earn ($9.90) per share for the year, down from their prior estimate of ($9.89). The consensus estimate for Moderna's current full-year earnings is ($9.43) per share.

Moderna (NASDAQ:MRNA - Get Free Report) last posted its quarterly earnings results on Thursday, November 7th. The company reported $0.03 earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.89) by $1.92. Moderna had a negative net margin of 43.77% and a negative return on equity of 17.68%. The firm had revenue of $1.90 billion during the quarter, compared to analyst estimates of $1.25 billion. During the same quarter in the prior year, the business posted ($1.39) earnings per share. The company's quarterly revenue was up 3.8% compared to the same quarter last year.

A number of other analysts also recently issued reports on MRNA. HSBC raised shares of Moderna from a "hold" rating to a "buy" rating and set a $58.00 price objective for the company in a report on Monday. Jefferies Financial Group decreased their price objective on shares of Moderna from $65.00 to $55.00 and set a "hold" rating on the stock in a research note on Tuesday, October 15th. Barclays decreased their price objective on shares of Moderna from $125.00 to $111.00 and set an "overweight" rating on the stock in a research note on Friday, November 8th. Royal Bank of Canada reissued a "sector perform" rating and issued a $75.00 price objective on shares of Moderna in a research note on Thursday, September 19th. Finally, Leerink Partners decreased their price objective on shares of Moderna from $60.00 to $48.00 and set an "underperform" rating on the stock in a research note on Tuesday, September 17th. Three equities research analysts have rated the stock with a sell rating, thirteen have given a hold rating, five have issued a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, the company has an average rating of "Hold" and a consensus price target of $84.00.

Moderna Stock Performance

Shares of MRNA traded down $0.60 during midday trading on Wednesday, reaching $36.69. The stock had a trading volume of 3,977,160 shares, compared to its average volume of 4,767,635. The firm has a 50 day simple moving average of $56.98 and a 200-day simple moving average of $95.46. Moderna has a one year low of $35.80 and a one year high of $170.47. The firm has a market cap of $14.12 billion, a PE ratio of -6.41 and a beta of 1.69. The company has a current ratio of 4.39, a quick ratio of 4.20 and a debt-to-equity ratio of 0.05.

Insiders Place Their Bets

In other Moderna news, CFO James M. Mock sold 715 shares of the business's stock in a transaction dated Monday, October 7th. The stock was sold at an average price of $60.12, for a total transaction of $42,985.80. Following the completion of the sale, the chief financial officer now directly owns 9,505 shares in the company, valued at $571,440.60. The trade was a 7.00 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Insiders have sold 2,930 shares of company stock worth $217,170 in the last three months. 15.20% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently modified their holdings of the company. Ashton Thomas Private Wealth LLC purchased a new position in shares of Moderna during the second quarter valued at approximately $26,000. Family Firm Inc. purchased a new position in Moderna during the second quarter worth approximately $33,000. Bank & Trust Co acquired a new stake in Moderna in the second quarter valued at approximately $36,000. Hanseatic Management Services Inc. purchased a new stake in shares of Moderna in the second quarter valued at approximately $48,000. Finally, Plato Investment Management Ltd lifted its position in shares of Moderna by 230.4% during the 2nd quarter. Plato Investment Management Ltd now owns 413 shares of the company's stock valued at $49,000 after buying an additional 288 shares in the last quarter. 75.33% of the stock is currently owned by institutional investors.

About Moderna

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.